Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antimicrobial Effectiveness01:28

Antimicrobial Effectiveness

198
The effectiveness of antimicrobial agents depends on various factors influencing their ability to eliminate microbial populations. Larger microbial populations require more time for complete eradication, emphasizing the importance of population size analysis when evaluating antimicrobial efficacy.Microbial resistance to antimicrobial agents varies significantly. Highly resilient microorganisms include endospores, gram-negative bacteria, and non-enveloped viruses, while prions are exceptionally...
198
Combined Effects of Drugs: Synergism01:27

Combined Effects of Drugs: Synergism

5.0K
Synergism is a useful mechanism where combining two or more drugs is more effective than each constituent used alone. Such combinations are also called supra-additive interactions. The drugs collectively enhance the final therapeutic effect by acting on different targets. Another advantage is that the low dose of each constituent drug is sufficient to achieve the desired effect. This helps reduce the duration of therapy and lower the adverse effects of these drugs.
Such synergistic combinations...
5.0K
Antibiotic Selection00:57

Antibiotic Selection

55.6K
Overview
55.6K
Urinary Tract Infection IV: Nursing Management01:17

Urinary Tract Infection IV: Nursing Management

106
In managing urinary tract infections (UTIs) in nursing, a comprehensive assessment is essential. Begin by gathering subjective data, such as the patient’s complaints of dysuria (painful urination), urinary frequency, urgency, suprapubic pain, and any lower abdominal discomfort. This information can be complemented by questions regarding previous UTIs, sexual activity, and personal hygiene practices, which can provide insight into risk factors. Objective assessment should focus on signs...
106
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein01:20

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

476
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
476
Pulmonary Tuberculosis IV01:26

Pulmonary Tuberculosis IV

216
Tuberculosis, more commonly referred to as TB, is an infectious disease stemming from Mycobacterium tuberculosis. While it primarily impacts the lungs, TB can also affect other body areas. Given its severity and global impact, timely and accurate diagnosis is crucial for controlling its spread and improving patient outcomes.
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...
216

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Methylprednisolone added to tocilizumab reduces mortality in SARS-CoV-2 pneumonia: An observational study.

Journal of internal medicine·2020
Same author

[Consensus document on pneumococcal vaccination in adults at risk by age and underlying clinical conditions. 2017 Update].

Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia·2017
Same journal

Nasal swab-guided deescalation of empirical linezolid in respiratory infections at a secondary-level hospital: quantification of quality gaps and antimicrobial stewardship opportunities.

Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia·2026
Same journal

[Infectious complications following intravesical bacillus Calmette-Guérin therapy: a case series].

Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia·2026
Same journal

Long-term persistence, effectiveness, safety, and metabolic impact of bictegravir/emtricitabine/tenofovir alafenamide fixed-dose combination in people living with HIV in the BICTARG cohort.

Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia·2026
Same journal

Associations between high-risk human papillomavirus genotypes: evidence of HPV16 predominance as a monoinfection and its no stronger link with high-grade lesions.

Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia·2026
Same journal

Pediatric septic arthritis caused by <i>Staphylococcus argenteus</i>.

Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia·2026
Same journal

[Colonisation or early invasion? Disseminated aspergillosis after bronchial isolation of <i>Aspergillus fumigatus</i> in a heart transplant recipient].

Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia·2026
See all related articles

Related Experiment Video

Updated: Sep 25, 2025

Author Spotlight: Scalable Drug Screening Protocol for Efficient Discovery of M. abscessus Treatments
07:50

Author Spotlight: Scalable Drug Screening Protocol for Efficient Discovery of M. abscessus Treatments

Published on: October 25, 2024

2.0K

Ceftazidime-avibactam.

F Sanz Herrero1

  • 1Francisco Sanz Herrero, Servicio de Neumología. Consorci Hospital General Universitari de València, Spain. sanz_fraher@gva.es.

Revista Espanola De Quimioterapia : Publicacion Oficial De La Sociedad Espanola De Quimioterapia
|April 30, 2022
PubMed
Summary
This summary is machine-generated.

Ceftazidime-avibactam is a promising treatment for nosocomial pneumonia caused by resistant Gram-negative bacteria. It shows comparable efficacy to carbapenems and better outcomes than colistin, with aztreonam addressing specific resistance mechanisms.

More Related Videos

Quadruple-Checkerboard: A Modification of the Three-Dimensional Checkerboard for Studying Drug Combinations
11:15

Quadruple-Checkerboard: A Modification of the Three-Dimensional Checkerboard for Studying Drug Combinations

Published on: July 24, 2021

4.9K
Optimized LC-MS/MS Method for the High-throughput Analysis of Clinical Samples of Ivacaftor, Its Major Metabolites, and Lumacaftor in Biological Fluids of Cystic Fibrosis Patients
06:14

Optimized LC-MS/MS Method for the High-throughput Analysis of Clinical Samples of Ivacaftor, Its Major Metabolites, and Lumacaftor in Biological Fluids of Cystic Fibrosis Patients

Published on: October 15, 2017

8.4K

Related Experiment Videos

Last Updated: Sep 25, 2025

Author Spotlight: Scalable Drug Screening Protocol for Efficient Discovery of M. abscessus Treatments
07:50

Author Spotlight: Scalable Drug Screening Protocol for Efficient Discovery of M. abscessus Treatments

Published on: October 25, 2024

2.0K
Quadruple-Checkerboard: A Modification of the Three-Dimensional Checkerboard for Studying Drug Combinations
11:15

Quadruple-Checkerboard: A Modification of the Three-Dimensional Checkerboard for Studying Drug Combinations

Published on: July 24, 2021

4.9K
Optimized LC-MS/MS Method for the High-throughput Analysis of Clinical Samples of Ivacaftor, Its Major Metabolites, and Lumacaftor in Biological Fluids of Cystic Fibrosis Patients
06:14

Optimized LC-MS/MS Method for the High-throughput Analysis of Clinical Samples of Ivacaftor, Its Major Metabolites, and Lumacaftor in Biological Fluids of Cystic Fibrosis Patients

Published on: October 15, 2017

8.4K

Area of Science:

  • Infectious Diseases
  • Microbiology
  • Pharmacology

Background:

  • Nosocomial infections caused by beta-lactamase-producing Gram-negative bacilli present significant therapeutic challenges.
  • Extended-spectrum beta-lactamase (ESBL)-producing Klebsiella pneumoniae and multidrug-resistant Pseudomonas aeruginosa are common pathogens in healthcare settings.
  • Carbapenems and colistin are often used, but resistance and toxicity are concerns.

Purpose of the Study:

  • To evaluate ceftazidime-avibactam as a therapeutic option for nosocomial pneumonia.
  • To compare the efficacy and safety of ceftazidime-avibactam with carbapenems and colistin.
  • To explore strategies for overcoming resistance to ceftazidime-avibactam.

Main Methods:

  • Clinical trials comparing ceftazidime-avibactam to carbapenems and colistin for nosocomial pneumonia.
  • Analysis of clinical cure rates, microbiological cure rates, and mortality.
  • In vitro studies assessing the efficacy of ceftazidime-avibactam in combination with aztreonam against metallo-beta-lactamase producers.

Main Results:

  • Ceftazidime-avibactam demonstrated non-inferiority to carbapenems in treating nosocomial pneumonia.
  • Ceftazidime-avibactam showed superior clinical and microbiological cure rates and improved mortality compared to colistin.
  • The combination of ceftazidime-avibactam and aztreonam effectively addressed infections caused by metallo-beta-lactamase-producing Enterobacteriaceae.

Conclusions:

  • Ceftazidime-avibactam is a valuable therapeutic option for nosocomial pneumonia caused by specific Gram-negative bacilli.
  • It offers an effective alternative to carbapenems and a safer profile than colistin.
  • Combination therapy with aztreonam expands its utility against resistant pathogens.